A treatment option for metastatic hormone-relapsed prostate cancer (mHRPC) cabazitaxel (Jevtana) has been recommended for use in combination with prednisone or prednisolone in England following a review by NICE.
NICE guidance (TA391) published this week acknowledges that cabazitaxel is both a clinically-effective and cost-effective treatment’ that prolongs life and is valued by patients.
Nick James, Professor of Clinical Oncology at the Cancer Centre at Queen Elizabeth Hospital in Birmingham, said: “I am delighted with this announcement from NICE, which represents an important milestone for men with advanced prostate cancer. It means that patients will now have access to another effective treatment, which may offer extended survival to patients who have failed on other treatments.”
Prostate cancer is currently the most common cancer in men and kills about 10,500 men in the UK every year. In time, most prostate cancers become resistant to hormone therapy and continue to grow despite treatment. Cabazitaxel is the only remaining NICE approved chemotherapy option for advanced prostate cancer which is not responsive to hormone therapies following initial chemotherapy (docetaxel).
NHS Wales and Health and Social Care (HSC) Northern Ireland are expected to adopt NICE guidance. Cabazitaxel is being appraised by the Scottish Medicines Consortium (SMC) through their Health Technology Appraisal (HTA) process. Guidance in Scotland is expected to be published by the SMC in June 2016.
“We believe that every man with advanced prostate cancer should have access to the treatments that works best for them and their needs,” commented Hugh Gunn, spokesperson for patients’ charity TACKLE Prostate Cancer. “This recommendation provides an important treatment for patients who are in the latter stages of the disease and who have few therapeutic options.”